Feed Articles

Jefferies predicts up to 500% upside for these two stocks with a "Strong Buy" rating

U.S. stocks experienced a strong comeback on Friday, with the S&P 500 index rising 1.59%, reversing a previous decline triggered by concerns about the impact of Donald Trump's tariffs on the world's largest economy.

Despite a difficult period for the biotech sector, Jefferies analyst Michael Yee sees opportunities for growth. According to his analysis, many biotech companies are trading below their cash value, presenting attractive investment opportunities for those who can identify the right catalysts, such as clinical trials, regulatory approvals and strategic launches.

Jefferies analysts have identified two biotech companies that have the potential to soar - one of which could jump as much as 500%.

Alto Neuroscience $ANRO

Alto Neuroscience is a clinical-stage biotechnology company focused on treating central nervous system (CNS) disorders and psychiatric diseases. It uses the principles of precision medicine to develop treatments for difficult-to-treat conditions such as depression, bipolar disorder and schizophrenia.

The company's key candidate is ALTO-300, an experimental antidepressant that is in a Phase 2b clinical trial. Alto expects to publish results in mid-2026. Other key drugs in development include ALTO-203 and ALTO-101, designed to treat anhedonia and cognitive deficits in schizophrenia.

Jefferies analyst Andrew Tsai sees great potential in Alto Neuroscience and rated the stock a "Buy" recommendation with a price target of $17, which would represent a 507% upside from the stock's current value.

Instil Bio $TIL

Instil Bio is a biotechnology company that originally developed tumor-infiltrating lymphocyte (TIL)-based therapies but has refocused its strategy on bispecific antibodies. In August 2024, the company entered into a partnership with China's ImmuneOnco Biopharmaceuticals, resulting in the licensing of two promising drugs.

The most interesting of these is SYN2510, a PD-L1xVEGF bispecific antibody. Studies are underway in China, where it is being tested in patients with lung cancer and triple-negative breast cancer. Expected clinical results in the second half of 2025 could have a large positive impact on the share price.

Jefferies analyst Kelly Shi gave Instil Bio a "Buy" rating and a $52 price target, implying a potential upside of 158%.

Disclaimer: You will find a lot of inspiration on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source: Tipranks

Stocks mentioned

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

Expensive oil was supposed to sink them; these 3 cruise lines instead report records and expect further growth

Oil this year soared to $138 per barrel, and cruise ships, which burn hundreds of thousands of tons of it annually, were supposed to be the first to suffer. Instead, all three largest cruise operators raised their profit outlooks, yet for a dollar of profit the market pays almost twice as much for…

MC
Milan Charvat
· 6h
Read more
BLACK

Man with Parkinson's stood up and walked away after an injection. The drugmaker's stock still fell 20%

A man with Parkinson's who couldn't get up from a chair walked out through the door on his own after a year of treatment with his own cells. The company behind the treatment raised $140.6 million in its IPO, and three weeks later its stock is 20% cheaper, even though there hasn't been a single…

MC
Milan Charvat
· 10h
Read more
BLACK

Dividends Above 10%? No Problem for These Stocks

A yield of over 15% a year sounds almost unbelievable in the stock market, yet several established US-listed securities are offering just that today. Mortgage REITs and leveraged bond funds earn money from the difference between the yield on mortgages or bonds and the cost of short-term financing,…

KJ
Kryštof Jáně
· 13h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy